Josphat Kosgei

442 total citations · 1 hit paper
9 papers, 64 citations indexed

About

Josphat Kosgei is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Josphat Kosgei has authored 9 papers receiving a total of 64 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Infectious Diseases, 4 papers in Virology and 2 papers in Epidemiology. Recurrent topics in Josphat Kosgei's work include HIV Research and Treatment (4 papers), HIV/AIDS drug development and treatment (4 papers) and HIV/AIDS Research and Interventions (3 papers). Josphat Kosgei is often cited by papers focused on HIV Research and Treatment (4 papers), HIV/AIDS drug development and treatment (4 papers) and HIV/AIDS Research and Interventions (3 papers). Josphat Kosgei collaborates with scholars based in United States, Kenya and Uganda. Josphat Kosgei's co-authors include Galit Alter, Leigh Anne Eller, Merlin L. Robb, Hannah Kibuuka, Susan H. Eshleman, Hendrik Streeck, Michael A. Eller, Bruce Schultz, Nelson L. Michael and Richard D. Moore and has published in prestigious journals such as Nature Medicine, Clinical Infectious Diseases and Journal of Virology.

In The Last Decade

Josphat Kosgei

5 papers receiving 64 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial

2024 47 citations Cissy Kityo, Ivan Mambule et al. The Lancet Infectious Diseases profile →

Peers

Josphat Kosgei

ID

VIROL

EPIDE

EM

IMMUN

Liviana Della Torre Italy

F. Harrison Omondi Canada

Yuwadee Phuang‐Ngern Thailand

Aude Christelle Ka’e Cameroon

Linda J Harrison United States

Amj Wensing Netherlands

Sara Modica Italy

Andrew Phillips United Kingdom

Holly R. Hack United States

Busisiwe Mlotshwa United States

Liviana Della Torre Italy

Josphat Kosgei

54 ×1.0

ID

50 ×1.1

VIROL

23 ×1.0

EPIDE

7 ×1.4

EM

6 ×1.2

IMMUN

Citations per year, relative to Josphat Kosgei Josphat Kosgei (= 1×) peers Liviana Della Torre

Countries citing papers authored by Josphat Kosgei

Since Specialization

Citations

This map shows the geographic impact of Josphat Kosgei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Josphat Kosgei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Josphat Kosgei more than expected).

Fields of papers citing papers by Josphat Kosgei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Josphat Kosgei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Josphat Kosgei. The network helps show where Josphat Kosgei may publish in the future.

Co-authorship network of co-authors of Josphat Kosgei

This figure shows the co-authorship network connecting the top 25 collaborators of Josphat Kosgei. A scholar is included among the top collaborators of Josphat Kosgei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Josphat Kosgei. Josphat Kosgei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Kityo, Cissy, Ivan Mambule, Simiso Sokhela, et al.. (2025). Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial. Nature Medicine. 32(1). 168–177.

2.

Ying, Roger, Tyler Hamby, Julius Tonzel, et al.. (2025). Knowledge, attitudes and practices related to SARS-CoV-2 prevention in Kenya. Journal of Public Health in Africa. 16(1). 1401–1401.

3.

Romo, Matthew L., Josphat Kosgei, Deborah Langat, et al.. (2024). Pre‐exposure prophylaxis implementation gaps among people vulnerable to HIV acquisition: a cross‐sectional analysis in two communities in western Kenya, 2021–2023. Journal of the International AIDS Society. 27(11). e26372–e26372. 2 indexed citations

4.

Kityo, Cissy, Ivan Mambule, Simiso Sokhela, et al.. (2024). Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial. The Lancet Infectious Diseases. 24(10). 1083–1092. 47 indexed citations breakdown →

5.

Tierney, Camlin, Deborah Persaud, Jennifer Jao, et al.. (2022). Infants Receiving Very Early Antiretroviral Therapy Have High CD4 Counts in the First Year of Life. Clinical Infectious Diseases. 76(3). e744–e747. 2 indexed citations

6.

Chen, Huichao, Victor Akelo, Josphat Kosgei, et al.. (2022). Brief Report: No Differences Between Lopinavir/Ritonavir and Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy on Clearance of Plasmodium falciparum Subclinical Parasitemia in Adults Living With HIV Starting Treatment (A5297).. PubMed. 89(2). 178–182.

7.

Shaffer, Douglas, Huichao Chen, Victor Akelo, et al.. (2021). Brief Report: No Differences Between Lopinavir/Ritonavir and Nonnucleoside Reverse Transcriptase Inhibitor–Based Antiretroviral Therapy on Clearance of Plasmodium falciparum Subclinical Parasitemia in Adults Living With HIV Starting Treatment (A5297). JAIDS Journal of Acquired Immune Deficiency Syndromes. 89(2). 178–182.

8.

Klock, Ethan, Leigh Anne Eller, Reinaldo E. Fernández, et al.. (2020). Impact of Early Antiretroviral Treatment Initiation on Performance of Cross-Sectional Incidence Assays. AIDS Research and Human Retroviruses. 36(7). 583–589. 6 indexed citations

9.

Eller, Michael A., Boonrat Tassaneetrithep, Bruce Schultz, et al.. (2019). Expansion of Stem Cell-Like CD4⁺Memory T Cells during Acute HIV-1 Infection Is Linked to Rapid Disease Progression. Journal of Virology. 93(14). 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact